Want to see ABBV full AI Analyst Report?
Top Page
AbbVie
(NYSE:ABBV)
Select Model
Select Model
Rating:61Neutral
Price Target:
$275.00
▲(31.97% Upside)
Action:Reiterated
Date:06/22/26
ABBV scores as moderately attractive, led by strong cash generation and a positive outlook from the latest earnings call (beat and guidance raise). Offsetting these strengths are elevated balance-sheet leverage/negative equity risk and a demanding valuation (very high P/E), while technical indicators remain broadly neutral.
Positive Factors
Cash generation
Sizable and growing operating and free cash flow is a durable strength: it funds R&D, capacity builds, BD and dividends without relying on equity markets. Consistent FCF (≈98% of net income) also supports debt servicing and strategic optionality over the medium term.
Negative Factors
High leverage
A very large debt load and volatile/negative equity materially raise financial risk. High leverage constrains flexibility for opportunistic BD or sustained buybacks, increases sensitivity to interest costs, and leaves less buffer if revenue or margins slip, despite strong FCF.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation
Sizable and growing operating and free cash flow is a durable strength: it funds R&D, capacity builds, BD and dividends without relying on equity markets. Consistent FCF (≈98% of net income) also supports debt servicing and strategic optionality over the medium term.
Read all positive factors
AbbVie Key Performance Indicators (KPIs)
Any
Revenue by Geography
Illustrates where AbbVie generates cash around the world and which regions drive growth or volatility. Geographic trends can flag where pricing pressure, local competition, or launch success will meaningfully affect total revenue and help assess the company’s ability to offset declines in one market with gains in another.
Illustrates where AbbVie generates cash around the world and which regions drive growth or volatility. Geographic trends can flag where pricing pressure, local competition, or launch success will meaningfully affect total revenue and help assess the company’s ability to offset declines in one market with gains in another.
Data provided by:
The Fly
The FlyAbbVie (ABBV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$461.26B
Dividend Yield2.87%
Average Volume (3M)5.53M
Price to Earnings (P/E)128.0
Beta (1Y)0.11
Revenue Growth9.50%
EPS Growth-13.63%
CountryUS
Employees55,000
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)2.04
Shares Outstanding1,766,792,800
10 Day Avg. Volume5,463,388
30 Day Avg. Volume5,532,482
Financial Highlights & Ratios
PEG Ratio-77.13
Price to Book (P/B)-124.40
Price to Sales (P/S)6.65
P/FCF Ratio22.83
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue7.23
Enterprise Value/Gross Profit10.23
Enterprise Value/Ebitda26.85
Forecast
1Y Price Target
$258.28Price Target Upside23.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)14.23
Revenue Forecast (FY)$67.32B
AbbVie Business Overview & Revenue Model
Company Description
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: ...
How the Company Makes Money
AbbVie makes money primarily by selling branded prescription drugs and related products, recognizing revenue when product control transfers to customers (e.g., wholesalers, specialty pharmacies, hospitals, government channels, and certain large pr...
AbbVie Earnings Call Summary
Earnings Call Date:Apr 29, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 31, 2026
Earnings Call Sentiment Positive
The call conveyed strong commercial momentum and financial performance with multiple product growth drivers (Skyrizi, Rinvoq, neuroscience portfolio) and a raised full-year outlook. Substantial pipeline progress (regulatory submissions, combination Crohn's data, obesity signal) and major manufacturing investments reinforce long-term growth positioning. Offsets include expected HUMIRA biosimilar erosion, pressure in some oncology and aesthetic segments, selected clinical setbacks/non-differentiation and near-term acquired IPR&D expense impacts. On balance, highlights — including robust sales beats, double-digit growth for key franchises, guidance raise, and encouraging pipeline readouts — outweigh the lowlights.Positive Updates
Quarterly Financial Beat and Guidance Raise
Adjusted EPS of $2.65, $0.07 above guidance midpoint; total net revenues of $15.0 billion, beating expectations by ~$300 million and representing 12.4% sales growth. Company raised full-year adjusted EPS guidance by $0.12 to $14.08–$14.28 and increased full-year revenue outlook to approximately $67.3 billion (+$300 million).
Negative Updates
HUMIRA Sales Decline from Biosimilars
HUMIRA global sales $688 million, down 40.3% (operational), reflecting expected biosimilar erosion and contributing to overall portfolio transitions.
Read all updates
Q1-2026 Updates
Positive
Negative
Quarterly Financial Beat and Guidance Raise
Adjusted EPS of $2.65, $0.07 above guidance midpoint; total net revenues of $15.0 billion, beating expectations by ~$300 million and representing 12.4% sales growth. Company raised full-year adjusted EPS guidance by $0.12 to $14.08–$14.28 and increased full-year revenue outlook to approximately $67.3 billion (+$300 million).
Read all positive updates
Company Guidance
AbbVie raised full‑year 2026 adjusted EPS guidance by $0.12 to $14.08–$14.28 (guidance excludes any estimate for acquired IPR&D beyond Q1) after a strong Q1 beat (adjusted EPS $2.65, $0.07 above midpoint; total net revenues $15.0B, +12.4% with a 2.1% FX tailwind). Management now expects full‑year net revenues of ~$67.3B (up $300M) and Q2 revenues of ~$16.7B (estimated 0.6% FX benefit); product assumptions include Skyrizi $21.6B (+$100M), Rinvoq $10.2B (+$100M) and total neuroscience $12.6B (+$100M). They forecast adjusted gross margin above 84% of sales (Q1 was 83.6%), adjusted R&D ≈$9.7B, adjusted SG&A ≈$14.2B, an adjusted operating margin of ~47.5% for the year (Q2 guide ≈50%), adjusted net interest expense ≈$2.7B (down $100M) and referenced a Q1 adjusted tax rate of 15.4%.AbbVie Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
38
Negative
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 62.82B | 61.16B | 56.33B | 54.32B | 58.05B | 56.20B |
| Gross Profit | 44.40B | 42.96B | 39.43B | 33.90B | 40.64B | 38.75B |
| EBITDA | 16.92B | 17.63B | 14.91B | 17.17B | 24.17B | 23.93B |
| Net Income | 3.64B | 4.23B | 4.28B | 4.86B | 11.84B | 11.54B |
Balance Sheet | ||||||
| Total Assets | 136.46B | 133.96B | 135.16B | 134.71B | 138.81B | 146.53B |
| Cash, Cash Equivalents and Short-Term Investments | 9.39B | 5.26B | 5.55B | 12.82B | 9.23B | 9.83B |
| Total Debt | 72.86B | 69.07B | 67.84B | 60.12B | 64.19B | 77.58B |
| Total Liabilities | 108.96B | 137.19B | 131.80B | 124.31B | 121.52B | 131.09B |
| Stockholders Equity | 27.50B | -3.27B | 3.33B | 10.36B | 17.25B | 15.41B |
Cash Flow | ||||||
| Free Cash Flow | 20.86B | 17.82B | 17.83B | 22.06B | 24.25B | 21.99B |
| Operating Cash Flow | 21.22B | 19.03B | 18.81B | 22.84B | 24.94B | 22.78B |
| Investing Cash Flow | -6.48B | -6.64B | -20.82B | -2.01B | -623.00M | -2.34B |
| Financing Cash Flow | -10.55B | -12.72B | -5.21B | -17.22B | -24.80B | -19.04B |
AbbVie Technical Analysis
Positive
208.38
Price Trends
218.62
Positive
217.71
Positive
219.75
Positive
Market Momentum
10.39
Negative
77.21
Negative
91.91
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABBV, the sentiment is Positive. The current price of 208.38 is below the 20-day moving average (MA) of 233.71, below the 50-day MA of 218.62, and below the 200-day MA of 219.75, indicating a bullish trend. The MACD of 10.39 indicates Negative momentum. The RSI at 77.21 is Negative, neither overbought nor oversold. The STOCH value of 91.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABBV.
AbbVie Risk Analysis
AbbVie disclosed 31 risk factors in its most recent earnings report. AbbVie reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AbbVie Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $319.99B | 36.38 | 17.93% | 3.12% | 2.70% | -48.28% | |
71 Outperform | $633.19B | 30.34 | 26.26% | 2.50% | 7.87% | -3.56% | |
71 Outperform | £225.47B | 28.77 | 22.41% | 1.53% | 4.64% | 26.75% | |
69 Neutral | $104.61B | 11.93 | 14.41% | 4.58% | 11.19% | -0.23% | |
64 Neutral | $138.61B | 18.56 | 8.37% | 6.65% | 1.36% | -5.39% | |
61 Neutral | $461.26B | 128.01 | 68.01% | 2.87% | 9.50% | -13.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ABBV
AbbVie
261.07
77.76
42.42%
JNJ
Johnson & Johnson
263.04
109.96
71.83%
MRK
Merck & Company
129.56
51.25
65.44%
PFE
Pfizer
24.32
0.60
2.52%
SNY
Sanofi
43.16
-3.29
-7.08%
GB:AZN
AstraZeneca
14,456.00
4,297.06
42.30%
AbbVie Corporate Events
Business Operations and StrategyM&A Transactions
AbbVie to Acquire Apogee, Expanding Immunology Portfolio
Positive
Jun 22, 2026
On June 22, 2026, AbbVie agreed to acquire clinical-stage biotech Apogee Therapeutics for $135.11 per share in cash, valuing the deal at about $10.9 billion and adding multiple inflammatory and immunological candidates to its pipeline. The all-cas...
Executive/Board ChangesShareholder Meetings
AbbVie Shareholders Back Directors, Maintain Governance Structure
Neutral
May 12, 2026
At AbbVie’s 2026 Annual Meeting of Stockholders held on May 8, 2026, shareholders elected four Class II directors—Jennifer L. Davis, Melody B. Meyer, Robert A. Michael and Frederick H. Waddell—to terms expiring in 2029 and ratifi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.